Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials
- 8 May 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet HIV
- Vol. 6 (7), e475-e482
- https://doi.org/10.1016/s2352-3018(19)30133-x
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with MenScience Translational Medicine, 2012
- How Good Is “Good Enough”? The Case for Varying Standards of Evidence According to Need for New Interventions in HIV PreventionAmerican Journal of Bioethics, 2012
- The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial resultsVaccine, 2011
- Some essential considerations in the design and conduct of non-inferiority trialsClinical Trials, 2011
- Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or conceptsStatistics in Medicine, 2010
- Ethics of Placebo-Controlled Trials of Zidovudine to Prevent the Perinatal Transmission of HIV in the Third WorldNew England Journal of Medicine, 1998
- Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human Immunodeficiency Virus in Developing CountriesNew England Journal of Medicine, 1997
- Statistical Issues in the Design of HIV Vaccine TrialsAnnual Review of Public Health, 1995
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989